|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Here we unveil key molecular mechanisms governing IL-27 biogenesis, an IL-12 family member that limits infections and autoimmunity.
|
30651310 |
2019 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we will review the role of IL-6 and IL-27 in inflammation, with a particular focus on inflammatory arthritis, and discuss their importance in the diagnosis, stratification and treatment of autoimmune disease.
|
29437229 |
2018 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-27 is predominantly synthesized by mononuclear phagocytes and exerts immunoregulatory functional activities on lymphocytic and nonlymphocytic cells during infection, autoimmunity or neoplasms.
|
28835457 |
2017 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-27 exerts protective effects in autoimmune diseases like experimental autoimmune encephalomyelitis; however, its role in the pathogenesis of osteoporosis remains to be determined.
|
28130449 |
2017 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Overall, our data show that IL-27 is a key cytokine in antigen-induced peripheral tolerance and may provide basis for improvement of antigen-specific tolerance approaches in multiple sclerosis and other autoimmune diseases.
|
29163476 |
2017 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Treg-specific IL-27Rα deletion uncovers a key role for IL-27 in Treg function to control autoimmunity.
|
28874534 |
2017 |
|
Autoimmune Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Accumulating data showed that IL-27 polymorphisms are linked to the susceptibility of some autoimmune diseases.
|
29754565 |
2017 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The regulatory effects of IL-27 on immune responses in autoimmune disease, infectious disease, and cancer are also discussed.
|
27734414 |
2016 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
In this review, we describe the current knowledge of the implications of IL-27 during the pathogenesis of infectious and autoimmune diseases.
|
23904441 |
2013 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
These data support the concept that IL-27, when provided exogenously, can induce a suppressive effect on SjS development and thus may be an effective therapeutic agent for regulating TH17 pro-inflammatory activity in autoimmune diseases where the TH17 system has been shown to play an important role in their pathogenesis.
|
22827855 |
2012 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
However, IL-27 also has potent inhibitory properties and mice that lack IL-27 mediated signaling develop exaggerated inflammatory responses in the context of infection or autoimmunity.
|
22608254 |
2012 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
These results show that IL-27 acts as a negative regulator of the developing IL-17A response in vivo, suggesting a potential therapeutic role for IL-27 in autoimmune diseases.
|
19380822 |
2009 |
|
Autoimmune Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In summary, our data indicate that genetic alterations in the coding regions of the IL-25 gene are unlikely to play a role in IBDs, but the c424C/A polymorphism in the IL-25 gene should be investigated for a potential association with other chronic inflammatory and inherited disorders such as autoimmune diseases.
|
14641539 |
2003 |